ALLO

Allogene Therapeutics Inc

NASDAQ: ALLO · HEALTHCARE · BIOTECHNOLOGY

$2.30

-7.84% today

Updated 2026-06-05

Market cap

$707.57M

P/E ratio

—

P/S ratio

7,784.36x

EPS (TTM)

$-0.77

Dividend yield

—

52W range

$1 – $4

Volume

10.8M

Market cap

$707.57M

P/E ratio

—

P/S ratio

7,784.36x

EPS (TTM)

$-0.77

Dividend yield

—

52W range

$1 – $4

Volume

10.8M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

3.7

Growth

6.5

Quality

3.0

Profitability

5.0

Valuation

C+

2/9

Piotroski F-Score

Weak

-6.2

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →202 stocks currently score above 75

Price targets

Analyst target

$8.35

+263.04%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

3 Strong Buy10 Buy2 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths

+ Debt/equity 0.29x — low leverage

Risks

- Piotroski 2/9 — weak financial health

- Altman Z -6.20 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-12.92M

- Revenue declining -100.00% QoQ

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$243000.00	$95000.00	$22000.00	$0.00	$0.00
Net income	$-329.81M	$-327.26M	$-257.59M	$-190.89M	$-42.61M
EPS	—	—	—	—	$-0.77
Free cash flow	$-225.71M	$-239.25M	$-200.99M	$-149.63M	$-12.92M
Profit margin	-135,726.34%	-344,489.47%	-1,170,863.64%	—	—

Recent insider activity

Date	Insider	Type	Shares	Price
2026-04-21	YOSHIYAMA, ANNIE	Sale	9,586	$2.31
2026-03-31	BENESKI, BENJAMIN MACHINAS	Sale	2,867	$2.50
2026-03-16	CHANG, DAVID D	Sale	47,763	$2.47

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
ALLO	$707.57M	25	3.7	3.0	5.0	6.5	—	Avoid
LLY	$948.95B	78	10.0	10.0	5.0	6.0	—	Strong Buy
JNJ	$536.54B	59	4.7	9.0	3.3	6.0	-71.41%	Buy
ABBV	$380.57B	63	4.0	8.0	4.0	5.0	-55.64%	Buy
UNH	$343.21B	54	5.3	5.5	4.7	5.5	-26.61%	Buy
MRK	$285.64B	50	3.3	8.0	2.7	5.0	-49.34%	Hold

Smart narrative

Allogene Therapeutics Inc trades at $2.30. Our Smart Value Score of 25/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of -6.20, it sits in the distress.

Frequently asked questions

What is Allogene Therapeutics Inc's stock price?

Allogene Therapeutics Inc (ALLO) trades at $2.30, on a P/S of 7,784.4x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.

Is Allogene Therapeutics Inc overvalued?

Allogene Therapeutics Inc carries a Smart Value Score of 25/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is the price target of Allogene Therapeutics Inc (ALLO)?

The 12-month analyst consensus target is $8.35, about 263.0% above the current $2.30. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Altman Z-Score?

Allogene Therapeutics Inc's Altman Z-Score is -6.20, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio7,784.36x

ROE-62.31%

Beta0.46

50D MA$2.30

200D MA$1.71

Shares out0.35B

Float0.27B

Short ratio—

Avg volume10.8M

Performance

1 week+0.00%

1 month-6.00%

3 months-22.95%

YTD+37.23%

1 year—

3 years—

5 years—

Compare

ALLO vs LLY →ALLO vs JNJ →ALLO vs ABBV →Stock screener →